ÐÇ¿ÕÓéÀÖ¹ÙÍø- BRFSS – ACBS 2023 Adult Prevalence Table 8

Print
Related Pages
Table 8: Estimated percent using inhaled short acting beta agonists among adults1 with current2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2023.
State/Territory Current
Sample
size±		 % SE§ 95% CI†
Arizona 394 55.8 4.2 (47.6 – 64.0)
California 296 53.1 4.5 (44.3 – 61.9)
Connecticut 463 49.3 3.7 (42.0 – 56.6)
Florida 385 51.7 5.2 (41.5 – 61.9)
Georgia 284 55.9 4.4 (47.3 – 64.5)
Hawaii 200 46.5 5.3 (36.1 – 56.9)
Indiana 540 58.8 2.8 (53.3 – 64.3)
Iowa 296 51.0 4.0 (43.2 – 58.8)
Kansas 255 55.6 4.6 (46.6 – 64.6)
Kentucky 225 49.6 6.4 (37.1 – 62.1)
Maine 399 60.2 4.0 (52.4 – 68.0)
Massachusetts 252 60.0 4.6 (51.0 – 69.0)
Michigan 518 55.7 2.9 (50.0 – 61.4)
Minnesota 463 48.2 3.4 (41.5 – 54.9)
Missouri 208 57.5 5.3 (47.1 – 67.9)
Montana 176 58.1 6.1 (46.1 – 70.1)
Nebraska 365 54.6 3.8 (47.2 – 62.0)
New Hampshire 386 53.2 4.0 (45.4 – 61.0)
New Jersey 302 39.3 3.8 (31.9 – 46.7)
New York 277 47.4 4.2 (39.2 – 55.6)
Ohio 381 59.3 3.8 (51.9 – 66.7)
Rhode Island 243 49.0 4.6 (40.0 – 58.0)
Texas 205 61.3 5.7 (50.1 – 72.5)
Utah 434 53.3 3.4 (46.6 – 60.0)
Vermont 466 57.2 3.1 (51.1 – 63.3)
Wisconsin 412 59.4 3.6 (52.3 – 66.5)
Puerto Rico 287 35.4 4.0 (27.6 – 43.2)
27 States / Area 9,112 53.7 1.2 (51.3 – 56.1)
Median 54.6
Range 35.4-61.3

 

1 Aged ≥ 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size for adults with current asthma, excludes “DK/Refused”

§ Standard error

† Confidence interval

Link for Summary Data Quality Report: /brfss/acbs/2023/pdf/sdq_report_acbs_23-508.pdf